Phase I: Primary Research Objective: Evaluate the safety, tolerability, and pharmacokinetic characteristics of a single dose of DGPR1008 in healthy subjects. Secondary Research Objective: Based on the safety and pharmacokinetic results, assess the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of DGPR1008.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Treatment-Emergent Adverse Events
Timeframe: through study completion, an average of 5 Days
Number of participants with abnormal vital signs
Timeframe: through study completion, an average of 5 Days
Number of participants with abnormal vital signs
Timeframe: through study completion, an average of 5 Days
Number of participants with abnormal vital signs
Timeframe: through study completion, an average of 5 Days
The number of participants with abnormal BMI
Timeframe: through study completion, an average of 5 Days
Number pf participants with abnormal laboratory tests results
Timeframe: through study completion, an average of 5 Days
Number pf participants with abnormal laboratory tests results
Timeframe: through study completion, an average of 5 Days
Number pf participants with abnormal laboratory tests results
Timeframe: through study completion, an average of 5 Days